The 2011 Infectious Disease Testing Market: US, Europe, Japan--Emerging Opportunities and Business Strategies for Suppliers15 Feb 2011 • by Natalie Aster
New York - The comprehensive worldwide survey is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding infectious disease testing market, in evaluating emerging opportunities and developing effective business strategies. The report “The 2011 Infectious Disease Testing Market: US, Europe, Japan--Emerging Opportunities and Business Strategies for Suppliers ” by Venture Planning Group provides a market segmentation analysis of over 70 diseases and viruses in seven countries, assessment of emerging technologies, review of current instrumentation, as well as strategic profiles of leading suppliers and recent market entrants with innovative technologies and products.
During 2009-2018, the infectious disease testing market will be driven to a large extent by the advances in science and technological innovation. Generally, in a technology-driven market, the successful suppliers are able to seize and exploit the new technology as a corporate strategic asset, which is managed along with business and marketing strategies. Integrating the new technology planning into business and corporate strategies will be the most challenging task facing the current and future suppliers of infectious disease testing products during the next ten years.
The advances in technology will expand the variety of the current product offering, including both instruments and reagent systems, which will demand new and innovative marketing skills. The new products will not only improve the current testing methodologies and make the diagnosis and treatment more specific and comprehensive, but will also contribute to the greater efficiency and cost-effectiveness of the medical practice. The successful marketing of these innovative products will require unconventional approaches to selling, promotion, distribution and service.
Published: April 2010
Price: US$ 28,700
Report Sample Abstract
Current and Emerging Technologies
The "ideal technology" for infectious disease testing would be required to have the following characteristics:
1. High sensitivity; 2. Ability to detect single microorganisms; 3. Ability to specifically detect either broad or narrow groups of organisms; 4. Ability to detect the presence of the target microorganisms regardless of the state of genetic expression in the sample; 5. Potential for developing simple and cost-effective rapid procedures, which could utilize the same basic format for a wide variety of tests.
The following technologies either individually or in combination with other technologies, appear to have the capability of meeting some or most of the requirements for the "ideal technology", and are expected to have a major impact on the infectious disease testing market during the next ten years.
During the next ten years, the major trend of potentially significant impact on the worldwide health care industry in general, and the infectious disease testing market specifically, will be the growing cost-containment pressures, which will become an equal concern of both the users and the suppliers. Overall, the cost-containment programs currently underway in all major countries are expected to change the health care market's mentality from "cost-plus" to a more business-like, "bottom line" orientation.
The trend toward the health care industry consolidation, including formation of associations, mergers, and other means of aggregation among hospitals, commercial/private laboratories, ambulatory care centers and physicians will also play an increasingly important role during the next ten years. The industry consolidation will result in a number of economic benefits to the health care providers, such as greater access to capital, better management, larger volume purchase discounts and increased marketing power. The new provider aggregations will include multi-hospital associations, for-profit and non-profit hospital chains, ambulatory and surgical care center franchises, physician group practices and others.
As part of this trend, the hospital system in many countries will undergo contraction during the next ten years. The hospitals most likely to survive will have more than 200 beds and will be associated with government or for-profit chains. As a result of the cost-containment efforts to limit the expansion of the number of hospital beds, some of the smaller hospitals will be closed. In order to achieve the economies of scale, many hospital laboratories are expected to increasingly enter the joint venture arrangements, e.g., when two or more closely-located hospitals use one of their laboratories as the major testing facility.
More information can be found in the report “The 2011 Infectious Disease Testing Market: US, Europe, Japan--Emerging Opportunities and Business Strategies for Suppliers ” by Venture Planning Group .
To order the report or ask for sample pages contact firstname.lastname@example.org